Focus Partners Advisor Solutions LLC Makes New $624,000 Investment in BioMarin Pharmaceutical Inc. $BMRN

Focus Partners Advisor Solutions LLC purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 10,899 shares of the biotechnology company’s stock, valued at approximately $624,000.

A number of other hedge funds have also recently modified their holdings of the business. CIBC Private Wealth Group LLC increased its stake in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares in the last quarter. Northwestern Mutual Investment Management Company LLC raised its holdings in BioMarin Pharmaceutical by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock worth $2,554,000 after purchasing an additional 183 shares during the period. Caerus Investment Advisors LLC lifted its position in BioMarin Pharmaceutical by 2.8% during the fourth quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock valued at $608,000 after purchasing an additional 278 shares in the last quarter. Chicago Partners Investment Group LLC lifted its position in BioMarin Pharmaceutical by 2.4% during the first quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 290 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares during the period. Institutional investors own 98.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Royal Bank Of Canada reduced their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. UBS Group reaffirmed a “neutral” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, July 14th. HC Wainwright boosted their price objective on BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Sanford C. Bernstein reduced their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Finally, Barclays increased their target price on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the stock an “overweight” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $88.45.

BioMarin Pharmaceutical Trading Down 1.1%

Shares of BioMarin Pharmaceutical stock opened at $66.64 on Tuesday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The company has a market capitalization of $12.90 billion, a P/E ratio of 180.11, a P/E/G ratio of 0.47 and a beta of 0.24. The company has a fifty day moving average of $59.76 and a 200 day moving average of $57.58.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. During the same period last year, the firm earned $1.44 earnings per share. The business’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, sell-side analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.22 earnings per share for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.